Armata Pharmaceuticals
ARMP
23 hedge funds and large institutions have $5.62M invested in Armata Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
116% more capital invested
Capital invested by funds: $2.6M → $5.62M (+$3.02M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
21% more funds holding
Funds holding: 19 → 23 (+4)
0.05% more ownership
Funds ownership: 4.66% → 4.71% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$639K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$297K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$238K |
| 4 |
Renaissance Technologies
New York
|
+$122K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$59K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.1K |
| 3 |
SSB
Sandy Spring Bank
Olney,
Maryland
|
-$3.09K |
| 4 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$492 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$15 |
ARMP Hedge Fund Activity: Q1 2021 in Review
23 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2021, worth a combined $5.62M — up 116% from $2.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARMP positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $639K. The largest seller was Stifel Financial, exiting entirely with an estimated $59K sold.
- 23 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2021, up from 19 in Q4 2020.
- Funds reported $5.62M of Armata Pharmaceuticals stock for Q1 2021, up 116% quarter-over-quarter.
- 6 funds opened new Armata Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of +4 holders.
- The largest Armata Pharmaceuticals buyer in Q1 2021 was Loomis, Sayles & Company, an estimated $639K added.
- The largest Armata Pharmaceuticals seller in Q1 2021 was Stifel Financial, an estimated $59K sold.
Based on aggregated 13F filings for Q1 2021.